
==== Front
Lupus Sci Med
Lupus Sci Med
lupusscimed
lupus
Lupus Science & Medicine
2053-8790
BMJ Publishing Group BMA House, Tavistock Square, London, WC1H 9JR

39266227
10.1136/lupus-2024-001210
lupus-2024-001210
Short Report
1506
Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021
https://twitter.com/jordanrobertsMD
http://orcid.org/0000-0002-0976-5697
Roberts Jordan E 12jordan.roberts@seattlechildrens.org

Faino Anna V 3Anna.Faino@seattlechildrens.org

Bryan Mersine A 12Mersine.Bryan@seattlechildrens.org

Cogen Jonathan D 24Jonathan.Cogen@seattlechildrens.org

Morgan Esi M 12esi.morgan@seattlechildrens.org

1 Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington, USA
2 Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA
3 Core for Biostatistics, Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, Washington, USA
4 Center for Research, Biology and Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Additional supplemental material is published online only. To view, please visit the journal online (https://doi.org/10.1136/lupus-2024-001210).

None declared.

Dr; jordan.roberts@seattlechildrens.org
2024
12 9 2024
11 2 e00121020 3 2024
29 8 2024
Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Abstract

Background

Rituximab is associated with high infection rates, but studies of infections following rituximab in youth with childhood-onset SLE (cSLE) are limited. We conducted a retrospective longitudinal cohort study to assess the incidence of hospitalised infections following rituximab among children with cSLE and to assess changes in hospital-based rituximab administration over time.

Methods

Youth ages 2–21 years with an International Classification of Diseases (ICD) code for SLE who received rituximab during admission to a Pediatric Health Information System hospital from 2009 to 2021 were included. Incidence rates for infections requiring hospitalisation over the 12 months following first rituximab administration were calculated. Rituximab use by year of hospital discharge was tabulated.

Results

We identified 1567 children with cSLE who received rituximab. 219 children were admitted with an infection within 1 year after first rituximab administration, for an incidence rate of 140 cases per 1000 patient-years. Seven children (0.44%) died during a hospitalisation with an infection in the year following rituximab administration. The most common hospitalised infections were bacterial pneumonia, sepsis and cellulitis. 12 children were hospitalised with COVID-19, none of whom died. Hospitalisations with rituximab administered decreased from 2019 to 2021.

Conclusions

In this cohort of patients with cSLE who received inpatient treatment with rituximab, we observed a 14% rate of hospitalisation with infection in the year following rituximab administration among youth with cSLE. Rituximab use declined during the COVID-19 pandemic. No fatalities with COVID-19 were observed. Given the lack of outpatient data, including doses of concomitant medications and disease activity measures, further research is needed to identify risk factors for infection following rituximab among children with cSLE.

Infections
Lupus Erythematosus, Systemic
Lupus Nephritis
Biological Products
Therapeutics
http://dx.doi.org/10.13039/100000980 Arthritis Foundation http://dx.doi.org/10.13039/100002193 Lupus Foundation of America http://dx.doi.org/10.13039/100017759 Childhood Arthritis and Rheumatology Research Alliance http://dx.doi.org/10.13039/100009993 Center for Clinical and Translational Research
==== Body
pmcIntroduction

Rituximab, an anti-CD20 B cell depleting monoclonal antibody, is associated with high rates of infection among adults with SLE and other conditions.1 2 An elevated risk of infection has also been shown among children receiving rituximab for autoimmune indications,35 but studies among children with childhood-onset SLE (cSLE) are limited. It is unknown how much risk is attributable to rituximab itself versus concomitantly administered immunosuppressants. Physician, patient and parent/caregiver concern for the immunosuppressive risks of rituximab may have increased since the emergence of SARS-CoV-2, as early studies showed high mortality among adults with rheumatological disease who contracted COVID-19 after receiving rituximab.68 However, the risk of severe COVID-19 among youth who received rituximab for cSLE remains poorly understood. We conducted a retrospective longitudinal cohort study to assess the incidence of hospitalised infections following first rituximab administration among children with cSLE. We also aimed to assess changes in hospital administration of rituximab over time, hypothesising that rituximab use declined after the start of the COVID-19 pandemic.

Methods

Children and adolescents ages 2–21 years with an International Classification of Diseases (ICD)-9 or ICD-10 code for SLE (710.0, M32*) and who received at least one dose of rituximab during admission to a Pediatric Health Information System (PHIS)-participating hospital from 2009 to 2021 were included. PHIS is a national administrative database with in-hospital billing data from over 50 free-standing children’s hospitals in the USA. These data include patient demographic data obtained from hospitals using standardised categories and payor types, discharge diagnosis codes, charges for intensive care unit (ICU) level of care (ICU ‘Flag’) and pharmacy administration data for drugs received during an inpatient or observation hospitalisation encounter.

Lupus organ involvement and disease severity were assessed using ICD-9 and ICD-10 codes for lupus nephritis, end-stage renal disease (ESRD), seizure, stroke and pulmonary haemorrhage at any time prior to first rituximab dose, and ICU admission during index hospitalisation for first rituximab dose. Infections were defined by ICD-9 and ICD-10 codes during an inpatient or observation encounter and were based on review of the literature. Codes that may have represented a manifestation of lupus itself (eg, undifferentiated fever) or were likely to represent a non-serious infection incidentally coded during hospitalisation for another indication were removed. Final codes included in the infection definition are listed in online supplemental table 1. In addition to a serious infection code, antibiotic use during the hospitalisation was also required for bacterial infections.

The observation period for infections was 12 months following the index hospitalisation with first rituximab administration. Summary statistics were used to describe children with cSLE who received rituximab and the subset who developed an infection. Coadministered immunosuppressive medications received during index hospitalisation for first rituximab administration and any inpatient encounter during 12 months of follow-up were reported. Due to the longer duration of action of cyclophosphamide, exposure was defined as receipt of cyclophosphamide up to 3 months prior to index hospitalisation for first rituximab or up to 12 months after. Incidence rates for infections requiring hospitalisation over the 12 months following first rituximab administration were calculated using exposure time truncated at time of death, first hospitalised infection or 12 months after index hospitalisation. Survival analysis using a Cox proportional hazard model was performed to assess the impact of patient characteristics (age, sex, race, ethnicity, lupus nephritis, ESRD, ICU admission at index hospitalisation) and concomitantly administered cyclophosphamide on time to hospitalised infection following first rituximab administration. Kaplan-Meier curve and log-rank test were also used to assess the impact of concomitant cyclophosphamide use on time to readmission with infection.

Inpatient rituximab administration by year of hospital discharge was tabulated from 2009 to 2021 in admissions with all length of stay (LOS) and short (≤1 day) LOS in order to assess trends in probable planned admissions for infusion. To account for changes in the number of cSLE admissions over time, the total admissions with rituximab and the proportion of cSLE admissions with rituximab administered were calculated.

Results

We identified 8588 children with cSLE, of whom 1567 received ≥1 dose of rituximab during admission to a PHIS-participating hospital. Those hospitalised with infection were similar to the overall cohort in demographic and clinical characteristics, although children with ESRD were over-represented among those with infection (11% of those readmitted with infection vs 5% of overall) (table 1). Medication exposures were also similar between groups, although slightly higher rates of all drug exposures were seen in those readmitted with infection. Of the entire rituximab cohort, 39% (n=604) received cyclophosphamide, compared with 44% of those who were readmitted with a serious infection.

Table 1 Characteristics of children with childhood-onset SLE who received rituximab and were hospitalised with infection

Variable	Total rituximab cohort(1567 children)	Not hospitalised with infection(1348 children with no infection-related hospitalisation within 1 year)	Hospitalised with infection(219 children with infection-related hospitalisation within 1 year)	
Age at admission (years), median (IQR)	15 (13–17)	15 (13–17)	15 (14–17)	
Female, n (%)	1286 (82)	1104 (82)	182 (83)	
Race/ethnicity, n (%)				
 Asian	108 (7)	100 (7)	8 (4)	
 Hispanic	482 (31)	403 (30)	79 (36)	
 Multiracial	21 (1)	19 (1)	2 (1)	
 Non-Hispanic black	578 (37)	496 (37)	82 (37)	
 Non-Hispanic white	265 (17)	232 (17)	33 (15)	
 Other	83 (5)	70 (5)	13 (6)	
 Unknown	30 (2)	28 (2)	2 (1)	
Insurance status, n (%)				
 Private	512 (33)	447 (33)	65 (30)	
 Public (non-military)	949 (61)	812 (60)	137 (63)	
 Military	37 (2)	31 (2)	6 (3)	
 Self-pay/uninsured	30 (2)	26 (2)	4 (2)	
 Other/unknown	39 (2)	32 (2)	7 (3)	
Household income, n (%)				
 <25 000	141 (9)	125 (10)	16 (8)	
 25 000–50 000	923 (61)	781 (60)	142 (67)	
 50 000–75 000	385 (25)	339 (26)	46 (22)	
 75 000–100 000	62 (4)	54 (4)	8 (4)	
 100 000 or more	14 (1)	13 (1)	1 (0)	
Lupus manifestations, n (%)				
 ICU flag at index hospitalisation	344 (22)	286 (21)	58 (26)	
 Lupus nephritis	951 (61)	786 (58)	165 (75)	
 End-stage renal disease	63 (4)	49 (4)	14 (6)	
 Stroke	47 (3)	41 (3)	6 (3)	
 Seizure	11 (1)	9 (1)	2 (1)	
 Pulmonary haemorrhage	32 (2)	30 (2)	2 (1)	
Concomitantly administered medications, n (%)				
 Methylprednisolone	1503 (96)	1293 (96)	210 (96)	
 Hydroxychloroquine	1211 (77)	1040 (77)	171 (78)	
 Prednisolone	1175 (75)	1007 (75)	168 (77)	
 Mycophenolate	684 (44)	574 (43)	110 (50)	
 Cyclophosphamide	608 (39)	512 (38)	96 (44)	
 Azathioprine	115 (7)	95 (7)	20 (9)	
 Tacrolimus	79 (5)	63 (5)	16 (7)	
 Methotrexate	54 (3)	47 (3)	7 (3)	
 Ciclosporin	30 (2)	22 (2)	8 (4)	
 Abatacept	4 (0)	4 (0)	0 (0)	
 Tocilizumab	2 (0)	2 (0)	0 (0)	
ICUintensive care unit

Of 1567 rituximab-treated children, 219 (14%, representing 339 hospitalisations) were readmitted with an infection within 1 year after the first rituximab administration, for an incidence rate of 140 cases per 1000 patient-years. Of the children readmitted with infection, 26% required ICU-level care. The median (IQR) time to hospitalisation with infection following rituximab was 1.83 (0.61–5.84) months. In a Cox proportional hazard model, only lupus nephritis (HR 1.94 (1.43, 2.63), p<0.001) was significantly associated with shorter time to readmission with serious infection (online supplemental table 2, online supplemental figure). Exposure to cyclophosphamide combined with rituximab was not associated with higher infection risk than rituximab (HR 1.05 (0.79, 1.39)).

The most common infections were bacterial pneumonia, sepsis and cellulitis (table 2). Twelve children were hospitalised with COVID-19 (4% of all hospitalised infections), of whom two required ICU-level care. There were no in-hospital deaths with COVID-19.

Table 2 Hospitalisation outcome by type of infection

Variable	All hospitalised infections (n=339)	ICU stay (n=88)	Death during hospitalisation (n=7)	
n (% of total hospitalisation)	n (% of hospitalisation with ICU)	n (% of total deaths)	
Type of infection				
 >1 serious infection code	61 (18)	31 (35)	5 (71)	
Bacterial				
 Bacterial pneumonia	78 (23)	26 (30)	2 (29)	
 Sepsis	69 (20)	45 (51)	5 (71)	
 Cellulitis	66 (19)	14 (16)	2 (29)	
 Urinary tract infection	43 (13)	4 (5)	0 (0)	
 Septic arthritis	3 (1)	0 (0)	0 (0)	
 Endocarditis	3 (1)	3 (3)	0 (0)	
 Bacterial meningitis	1 (0)	1 (1)	0 (0)	
 Bacterial encephalitis	1 (0)	0 (0)	0 (0)	
 Osteomyelitis	0 (0)	0 (0)	0 (0)	
Fungal				
 Aspergillosis	20 (6)	7 (8)	0 (0)	
 Candidiasis	17 (5)	7 (8)	2 (29)	
 Non-tuberculosis or unspecified mycobacterial	6 (2)	0 (0)	0 (0)	
 Other mycoses	4 (1)	4 (5)	1 (14)	
 Pneumocystis jirovecii pneumonia	2 (1)	2 (2)	1 (14)	
 Cryptococcus	2 (1)	1 (1)	0 (0)	
 Histoplasmosis	1 (0)	0 (0)	0 (0)	
 Coccidioidomycosis	1 (0)	0 (0)	0 (0)	
 Tuberculosis	0 (0)	0 (0)	0 (0)	
Viral				
 Herpes simplex	45 (13)	9 (10)	1 (14)	
 Influenza	15 (4)	3 (3)	0 (0)	
 COVID-19	12 (4)	2 (2)	0 (0)	
 Herpes zoster	11 (3)	1 (1)	0 (0)	
 Cytomegalovirus	11 (3)	1 (1)	1 (14)	
 Other viral pneumonia	11 (3)	6 (7)	1 (14)	
 Varicella	7 (2)	1 (1)	0 (0)	
 Adenovirus	1 (0)	1 (1)	0 (0)	
 Epstein-Barr virus	0 (0)	0 (0)	0 (0)	
 Progressive multifocal leucoencephalopathy	0 (0)	0 (0)	0 (0)	
 Other viral encephalitis	0 (0)	0 (0)	0 (0)	
ICUintensive care unit

Seven children with cSLE (0.44%) died during hospitalisation with an infection in the first year following rituximab administration. Of these seven children, 71% (n=5) had multiple infection codes. The most common infections among those who died included sepsis (n=5), bacterial pneumonia (n=2), cellulitis (n=2) and systemic candidiasis (n=2). Other infections observed in cases of in-hospital mortality included cytomegalovirus, herpes simplex, Pneumocystis jirovecii pneumonia, other viral pneumonia and other mycoses (n=1 for each diagnosis).

The total number of hospitalisations with rituximab administered decreased from 324 in 2019 to 299 in 2020 and 264 in 2021. Among those hospitalisations with LOS ≤1 day, the number with rituximab administered decreased from 89 in 2019 to 60 in 2020 and 57 in 2021. The proportion of short LOS admissions with rituximab administered plateaued and decreased starting in 2016, while a decrease in both short and total LOS admissions with rituximab administered was observed starting in 2020 (figure 1).

Figure 1 Proportion of hospitalisations with rituximab administered by discharge year and length of stay (LOS).

Discussion

We observed high rates of infection after rituximab administration in a multicentre cohort of youth with cSLE. This is the largest cohort of children with cSLE who received rituximab in which the types and incidence of hospitalised infections have been evaluated. The overall rate of hospitalisation for infection in the year following rituximab among our cohort exceeded that previously reported in a large Medicaid-insured cohort of children with cSLE.9 As demonstrated in that cohort,9 and our previous investigations of children with cSLE using PHIS,10 bacterial pneumonia was the single largest contributing infection. Viral and fungal infections were also common, including influenza, herpes simplex virus and herpes zoster. Several prevalent infections were potentially vaccine-preventable, including bacterial pneumonia, influenza and herpes zoster. We observed one death from P. jirovecii pneumonia. Due to lack of outpatient medication data, we were unable to ascertain if this child had received Pneumocystis prophylaxis, although the use of prophylaxis is controversial in the management of paediatric and adult SLE and has not routinely been given following rituximab.1114

Rituximab use declined during the COVID-19 pandemic. This may indicate more hesitancy regarding rituximab use in cSLE care. Despite the possibility of concern for severe COVID-19 leading to reductions in rituximab use, no fatalities during hospitalisations with COVID-19 were observed in our cohort. We also observed a decline in short LOS admissions with rituximab that preceded the pandemic, which may indicate a shift of more routine cSLE care towards infusion centre rather than inpatient settings. This trend may have increased following COVID-19.

Our study has several limitations. Concomitant use of other highly immunosuppressive medications administered inpatient, including methylprednisolone and cyclophosphamide,15 was common, which may have contributed to infection risk. Although other immunomodulator use was similar in those who did and did not have an infection, and cyclophosphamide was not an independent risk factor for hospitalised infection in our cohort in multivariable regression, a limitation of our approach is that PHIS does not contain outpatient prescription data. Therefore, concomitant immunomodulator use may have been underestimated, and there is a risk of ascertainment bias if oral medications usually received in the outpatient setting were observed at a higher rate among those with additional hospitalisations during the observation period. We were unable to conclusively assess the additional risk of rituximab itself by comparing children with similar background immunosuppressant use, including comparable glucocorticoid doses. This limitation highlights the need for more comprehensive data sources that include both inpatient and outpatient cSLE treatment data, and a future direction of this work includes linkages to other data sets to perform more robust pharmacoepidemiological studies of cSLE treatment.

As many children receive their first rituximab dose while inpatient and the subsequent doses at outpatient infusion centres, we were not able to determine the total number of doses received and we did not have laboratory data to confirm B cell depletion or assess hypogammaglobulinaemia, which are known risk factors for post-rituximab infection.1 5 Finally, while individual participants can be tracked through multiple hospitalisations at different PHIS-participating hospitals, we cannot rule out that children may have received rituximab prior to the index hospitalisation at non-participating hospitals or outpatient infusion centres not captured in our data set. It is possible that these data set limitations set may lead to overestimation of the infection risks of rituximab in youth with cSLE, or limit the generalisability of our findings, as the population of patients with cSLE who received rituximab while inpatient may include sicker patients than those who receive rituximab solely in outpatient settings.

Our results, including the prevalence of infections which are potentially preventable by prophylactic medication and vaccination, may guide the use of preventative care measures and help target quality improvement efforts to reduce the risk of readmission and death from infection in this high-risk population.16 Further research is needed to understand the additional risk of rituximab compared with conventional disease-modifying antirheumatic drugs and glucocorticoids alone, and to identify modifiable risk factors for infection following rituximab among children with cSLE.

supplementary material

10.1136/lupus-2024-001210 online supplemental file 1

10.1136/lupus-2024-001210 online supplemental file 2

10.1136/lupus-2024-001210 online supplemental file 3

Data availability statement

Data are available upon reasonable request.

Funding: JER was supported by grants from the Lupus Foundation of America, the Childhood Arthritis and Rheumatology Research Alliance-Arthritis Foundation, and the Center for Clinical and Translational Research, Seattle Children’s Research Institute.

Provenance and peer review: Not commissioned; externally peer reviewed.

Patient consent for publication: Not required.

Ethics approval: This study involves human participants and was approved by the Seattle Children’s Hospital Institutional Review Board (protocol #00003955). The study was determined exempt due to minimal risk and use of secondary data only. PHIS data use was approved by the Children’s Hospital Association. This was an exempt study not requiring consent due to use of secondary data only.

Presented at: Data included in this manuscript were previously published as a conference abstract: Roberts J, Faino A, Bryan M, Cogen J, Morgan E. Serious infections following rituximab administration in children with systemic lupus erythematosus (abstract). Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/serious-infections-following-rituximab-administration-in-children-with-systemic-lupus-erythematosus/.

Data availability free text: Deidentified data may be provided upon request pending approval of the Seattle Children’s Hospital IRB and the Children’s Hospital Association.
==== Refs
References

1 Barmettler S Ong MS Farmer JR et al Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia JAMA Netw Open 2018 1 e184169 10.1001/jamanetworkopen.2018.4169 30646343
2 Luna G Alping P Burman J et al Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies JAMA Neurol 2020 77 184 91 10.1001/jamaneurol.2019.3365 31589278
3 Dale RC Brilot F Duffy LV et al Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease Neurology (ECronicon) 2014 83 142 50 10.1212/WNL.0000000000000570
4 McAtee CL Lubega J Underbrink K et al Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults JAMA Netw Open 2021 4 e2036321 10.1001/jamanetworkopen.2020.36321 33533931
5 Ong MS Rothman D Barmettler S et al New-onset hypogammaglobulinaemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases Rheumatology (Oxford) 2022 61 1610 20 10.1093/rheumatology/keab626 34329428
6 Gianfrancesco M Hyrich KL Al-Adely S et al Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry Ann Rheum Dis 2020 79 859 66 10.1136/annrheumdis-2020-217871 32471903
7 Fernandez-Ruiz R Paredes JL Niewold TB COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease Transl Res 2021 232 13 36 10.1016/j.trsl.2020.12.007 33352298
8 Ugarte-Gil MF Alarcón GS Izadi Z et al Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance Ann Rheum Dis 2022 81 970 8 10.1136/annrheumdis-2021-221636 35172961
9 Hiraki LT Feldman CH Marty FM et al Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid Arthritis Care Res (Hoboken) 2017 69 1620 6 10.1002/acr.23219 28217919
10 Roberts JE Faino A Bryan MA et al Hospitalization and Mortality Due to Infection Among Children and Adolescents With Systemic Lupus Erythematosus in the United States J Rheumatol 2024 51 891 8 10.3899/jrheum.2023-1219 38561187
11 Schmajuk G Jafri K Evans M et al Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs Semin Arthritis Rheum 2019 48 1087 92 10.1016/j.semarthrit.2018.10.018 30449650
12 Wang W-H Lai C-C Huang Y-F et al Pneumocystis Jirovecii Pneumonia in Systemic Lupus Erythematosus: A Nationwide Cohort Study in Taiwan Arthritis Care Res (Hoboken) 2022 74 1444 50 10.1002/acr.24584 33645012
13 Boone B Lazaroff SM Wheless L et al Rates of Pneumocystis jirovecii pneumonia and prophylaxis prescribing patterns in a large electronic health record cohort of patients with systemic lupus erythematosus Semin Arthritis Rheum 2022 57 152106 10.1016/j.semarthrit.2022.152106 36279805
14 Kapoor TM Mahadeshwar P Nguyen S et al Low prevalence of Pneumocystis pneumonia in hospitalized patients with systemic lupus erythematosus: review of a clinical data warehouse Lupus (Los Angel) 2017 26 1473 82 10.1177/0961203317703494
15 Opastirakul S Chartapisak W Infection in children with lupus nephritis receiving pulse and oral cyclophosphamide therapy Pediatr Nephrol 2005 20 1750 5 10.1007/s00467-005-2032-4 16133037
16 Harris JG Harris LA Olarte L et al Improving Pneumococcal Vaccination Rates in High-risk Children in Specialty Clinics Pediatrics 2022 149 e2020031724 10.1542/peds.2020-031724 35233616
